Satellite Symposium | Sequencing of therapy for a patient with TP53-mutated MCL

The virtual Lymphoma Hub Satellite Symposium, at the 16th International Conference on Malignant Lymphoma (16-ICML), saw a panel of international experts come together to discuss the sequencing of therapies in high-risk relapsed/refractory lymphoma and chronic lymphocytic leukemia. Professor Steven Le Gouill, CHU de Nantes, Nantes, FR, discusses sequencing of therapy for patients with TP53-mutated mantle cell lymphoma (MCL).

Le Gouill begins by presenting a patient case and discussing the significance of prognostic markers, especially for relapsed cases. The presentation outlines prognostic data around relevant MCL patient characteristics, including the MANTLE-FIRST trial. Le Gouill goes on to review currently available treatment options, as well as introducing novel agents in MCL. Finally, he discusses the encouraging results of the AIM and OAsIs trials, which combine ibrutinib and venetoclax, and ibrutinib, venetoclax, and obinutuzumab, respectively.